73 related articles for article (PubMed ID: 15326488)
1. Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cells.
Kalaitzidis D; Ok J; Sulak L; Starczynowski DT; Gilmore TD
Oncogene; 2004 Sep; 23(45):7580-7. PubMed ID: 15326488
[TBL] [Abstract][Full Text] [Related]
2. A conditional mutant of vRel containing sequences from the human estrogen receptor.
Capobianco AJ; Gilmore TD
Virology; 1993 Mar; 193(1):160-70. PubMed ID: 8438564
[TBL] [Abstract][Full Text] [Related]
3. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
Starczynowski DT; Reynolds JG; Gilmore TD
Oncogene; 2005 Nov; 24(49):7355-68. PubMed ID: 16027730
[TBL] [Abstract][Full Text] [Related]
4. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel.
Gilmore TD; Cormier C; Jean-Jacques J; Gapuzan ME
Oncogene; 2001 Oct; 20(48):7098-103. PubMed ID: 11704834
[TBL] [Abstract][Full Text] [Related]
5. A chicken c-Rel-estrogen receptor chimeric protein shows conditional nuclear localization, DNA binding, transformation and transcriptional activation.
Zurovec M; Petrenko O; Roll R; Enrietto PJ
Oncogene; 1998 Jun; 16(24):3133-42. PubMed ID: 9671392
[TBL] [Abstract][Full Text] [Related]
6. Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity.
Starczynowski DT; Trautmann H; Pott C; Harder L; Arnold N; Africa JA; Leeman JR; Siebert R; Gilmore TD
Oncogene; 2007 Apr; 26(19):2685-94. PubMed ID: 17072339
[TBL] [Abstract][Full Text] [Related]
7. Envelope-dependent transactivation by the retroviral oncoprotein v-Rel is required for efficient malignant transformation of chicken spleen cells.
Epinat JC; Dvorin EL; Gilmore TD
Oncogene; 2000 Jun; 19(28):3131-7. PubMed ID: 10918567
[TBL] [Abstract][Full Text] [Related]
8. Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain.
Sarkar S; Gilmore TD
Oncogene; 1993 Aug; 8(8):2245-52. PubMed ID: 8336947
[TBL] [Abstract][Full Text] [Related]
9. v-Rel prevents apoptosis in transformed lymphoid cells and blocks TNFalpha-induced cell death.
Zong WX; Farrell M; Bash J; Gélinas C
Oncogene; 1997 Aug; 15(8):971-80. PubMed ID: 9285692
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional activation and transformation by chimaeric Fos-estrogen receptor proteins: altered properties as a consequence of gene fusion.
Schuermann M; Hennig G; Müller R
Oncogene; 1993 Oct; 8(10):2781-90. PubMed ID: 8378087
[TBL] [Abstract][Full Text] [Related]
11. Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells.
Starczynowski DT; Reynolds JG; Gilmore TD
Oncogene; 2003 Oct; 22(44):6928-36. PubMed ID: 14534540
[TBL] [Abstract][Full Text] [Related]
12. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
Epinat JC; Kazandjian D; Harkness DD; Petros S; Dave J; White DW; Gilmore TD
Oncogene; 2000 Feb; 19(5):599-607. PubMed ID: 10698504
[TBL] [Abstract][Full Text] [Related]
13. An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activation.
Fan Y; Gélinas C
Oncogene; 2007 Jun; 26(27):4038-43. PubMed ID: 17173064
[TBL] [Abstract][Full Text] [Related]
14. The suppression of SH3BGRL is important for v-Rel-mediated transformation.
Majid SM; Liss AS; You M; Bose HR
Oncogene; 2006 Feb; 25(5):756-68. PubMed ID: 16186799
[TBL] [Abstract][Full Text] [Related]
15. Characterization of changes in gene expression associated with malignant transformation by the NF-kappaB family member, v-Rel.
Petrenko O; Ischenko I; Enrietto PJ
Oncogene; 1997 Oct; 15(14):1671-80. PubMed ID: 9349500
[TBL] [Abstract][Full Text] [Related]
16. NF-kappaB and estrogen receptor alpha interactions: Differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells.
Gionet N; Jansson D; Mader S; Pratt MA
J Cell Biochem; 2009 Jun; 107(3):448-59. PubMed ID: 19350539
[TBL] [Abstract][Full Text] [Related]
17. The activation of TC10, a Rho small GTPase, contributes to v-Rel-mediated transformation.
Tong S; Liss AS; You M; Bose HR
Oncogene; 2007 Apr; 26(16):2318-29. PubMed ID: 17016434
[TBL] [Abstract][Full Text] [Related]
18. v-Myb represses the transcription of Ets-2.
Wang DM; Sevcikova S; Wen H; Roberts S; Lipsick JS
Oncogene; 2007 Feb; 26(8):1238-44. PubMed ID: 16909100
[TBL] [Abstract][Full Text] [Related]
19. Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity.
Maru BS; Tobias JH; Rivers C; Caunt CJ; Norman MR; McArdle CA
Bone; 2009 Jan; 44(1):102-12. PubMed ID: 18976723
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor inhibits interleukin-6 gene expression by disruption of nuclear factor kappaB transactivation.
Liu H; Liu K; Bodenner DL
Cytokine; 2005 Aug; 31(4):251-7. PubMed ID: 16043358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
